Codexis, Inc.
NASDAQ:CDXSBiotechnology
Healthcare
$1.15 +0.60%
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
52W Low $0.96High $3.87
Volume 1.47M
Average 1.15M
Income Statement
Follow revenue through to earnings.
Revenue
$70.39M
FY 2025 · Annual
+18.6% YoYOperating Income
-$38.33M
FY 2025 · Annual
Net Income
-$43.97M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 104.75M | 138.59M | 70.14M | 59.35M | 70.39M |
| Cost of Revenue | 22.21M | 38.03M | 12.81M | 16.29M | 9.34M |
| Gross Profit | 82.55M | 100.56M | 57.33M | 43.06M | 61.05M |
| Gross Margin | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% |
| Research & Development | 55.92M | 80.1M | 58.89M | 46.26M | 52.31M |
| Selling, General & Admin | 49.32M | 52.17M | 53.25M | 55.15M | 47.07M |
| Operating Expenses | 105.24M | 135.44M | 125.4M | 101.58M | 99.38M |
| Depreciation & Amortization | 5.95M | 5.4M | 5.52M | 4.95M | 5.25M |
| EBITDA | (15.14M) | (26.31M) | (49.28M) | (53.41M) | (33.87M) |
| EBITDA Margin | -14.5% | -19.0% | -70.3% | -90.0% | -48.1% |
| Operating Income | (22.7M) | (34.88M) | (68.07M) | (58.52M) | (38.33M) |
| Operating Margin | -21.7% | -25.2% | -97.0% | -98.6% | -54.5% |
| Interest Income | 459K | 1.44M | 4.17M | 3.67M | 2.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 4.81M |
| Other Income / Expenses | 1.61M | 1.57M | (8.1M) | (6.72M) | (5.6M) |
| Income Before Tax | (21.09M) | (33.32M) | (76.17M) | (65.24M) | (43.93M) |
| Pre-Tax Margin | -20.1% | -24.0% | -108.6% | -109.9% | -62.4% |
| Income Tax Expense | 189K | 276K | 69K | 34K | 47K |
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Net Margin | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| EPS (Basic) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| EPS (Diluted) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| 64.57M | 65.34M | 68.13M | 73.41M | 87.14M | |
| 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
CDXS Earnings Waterfall · TTM
NASDAQ:CDXS · Revenue to Net Income
Key Ratios
EPS$-0.37
Gross Margin79.7%
Net Margin-86.8%
P/E Ratio-1.8
P/S Ratio13.2
Analysis
$78.1M of revenue converted into -$32.0M of net income for the selected period. Gross margin is 79.7% and net margin is -86.8%, showing how much revenue survives after costs and taxes. EPS is $-0.37, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 |
How much revenue does CDXS generate?
Codexis, Inc. (CDXS) reported $70.39M of revenue in fiscal 2025.
Is CDXS profitable?
Codexis, Inc. (CDXS) reported -$43.97M of net income, with a net margin of -62.5%.
Continue the stock analysis
Jump to another research area for this company.